Article Text

other Versions

PDF
Original article
Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2
  1. Patrizia Calandra1,
  2. Isabella Cascino1,
  3. Richard J L F Lemmers2,
  4. Giuliana Galluzzi1,
  5. Emanuela Teveroni1,3,
  6. Mauro Monforte4,
  7. Giorgio Tasca5,
  8. Enzo Ricci4,
  9. Fabiola Moretti1,
  10. Silvère M van der Maarel2,
  11. Giancarlo Deidda1
  1. 1Institute of Cell Biology and Neurobiology, National Research Council of Italy, Monterotondo (Rome), Italy
  2. 2Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
  3. 3Institute of Pathology, Catholic University School of Medicine, Rome, Italy
  4. 4Institute of Neurology, Catholic University School of Medicine, Rome, Italy
  5. 5Don Carlo Gnocchi Onlus Foundation, Milan, Italy.
  1. Correspondence to Dr Giancarlo Deidda, Institute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Monterotondo Scalo, 00015, (Rome), Italy; giancarlo.deidda{at}cnr.it

Abstract

Background Facioscapulohumeral muscular dystrophy (FSHD) is associated with an epigenetic defect on 4qter. Two clinically indistinguishable forms of FSHD are known, FSHD1 and FSHD2. FSHD1 is caused by contraction of the highly polymorphic D4Z4 macrosatellite repeat array on chromosome 4q35. FSHD2 is caused by pathogenic mutations of the SMCHD1 gene.

Both genetic defects lead to D4Z4 DNA hypomethylation. In the presence of a polymorphic polyadenylation signal (PAS), DNA hypomethylation leads to inappropriate expression of the D4Z4-encoded DUX4 transcription factor in skeletal muscle. Currently, hypomethylation is not diagnostic per se because of the interference of non-pathogenic arrays and the lack of information about the presence of DUX4-PAS.

Methods We investigated, by bisulfite sequencing, the DNA methylation levels of the region distal to the D4Z4 array selectively in PAS-positive alleles.

Results Comparison of FSHD1, FSHD2 and Control subjects showed a highly significant difference of methylation levels in all CpGs tested. Importantly, using a cohort of 112 samples, one of these CpGs (CpG6) is able to discriminate the affected individuals with a sensitivity of 0.95 supporting this assay potential for FSHD diagnosis. Moreover, our study showed a relationship between PAS-specific methylation and severity of the disease.

Conclusions These data point to the CpGs distal to the D4Z4 array as a critical region reflecting multiple factors affecting the epigenetics of FSHD. Additionally, methylation analysis of this region allows the establishment of a rapid and sensitive tool for FSHD diagnosis.

  • Clinical genetics
  • Diagnosis
  • Molecular genetics
  • Muscle disease
  • Diagnostics tests

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.